Lymphotoxin alpha1 beta2 heterotrimer (LT-alpha1-beta2)

The Lymphotoxin alpha1 beta2 heterotrimer (LT-alpha1-beta2) is a membrane-anchored cytokine belonging to the tumor necrosis factor (TNF) superfamily, composed of one lymphotoxin-alpha subunit and two lymphotoxin-beta subunits (UniProt: P01374, Q06643). It acts as the primary ligand for the Lymphotoxin Beta Receptor (LTBR) and is essential for the development and structural organization of secondary lymphoid organs, such as lymph nodes and Peyer's patches (PMID: 17540445). By inducing the expression of homeostatic chemokines like CXCL13 and CCL21, the LT-alpha1-beta2/LTBR signaling axis regulates the trafficking of T and B cells within immune tissues (PMID: 15814605). In chronic inflammatory conditions, such as Sjögren's syndrome and rheumatoid arthritis, the overexpression of this heterotrimer drives the formation of ectopic tertiary lymphoid structures that exacerbate autoimmunity (PMID: 21901126). Additionally, the pathway has been implicated in tumor progression and the maintenance of chronic inflammatory microenvironments in various cancers. Therapeutic strategies targeting LT-alpha1-beta2 include the use of decoy receptors like baminercept or monoclonal antibodies like pateclizumab to block LTBR activation and reduce pathological inflammation (PMID: 24432168). While effective in modulating the immune response, inhibition of this target carries risks of impaired host defense and altered immune system architecture.

Other names

LT-alpha1-beta2Membrane-bound lymphotoxinLymphotoxin-alpha/beta complexLT-alpha/beta heterotrimerLTA1B2

Neutralization of the heterotrimeric ligand or competitive inhibition via a decoy receptor to prevent binding to the lymphotoxin-beta receptor (LTBR)